[{"id":"f7695ad1-b45e-4730-91c7-647f1926ad81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05207722","created_at":"2022-01-26T13:53:54.866Z","updated_at":"2024-07-02T16:35:55.389Z","phase":"Phase 1/2","brief_title":"CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","source_id_and_acronym":"NCT05207722","lead_sponsor":"Celularity Incorporated","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cyclophosphamide • CYNK-101 • fludarabine IV • mesna • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2025","study_completion_date":" 02/15/2025","last_update_posted":"2023-02-16"}]